Boost GVAX Pancreas Vaccine With or Without CY in Patients With Pancreas Cancer

Inclusion Criteria

• •1. Has a history of surgically resected and pathologically proved AJCC stage I or stage II adenocarcinoma of the head, neck, or uncinate of the pancreas.
• •2. Cohorts 1, 3, 4 and 5: Have been a participant in Hopkins IRB protocol J0810, J1568, J15237 or J1766.
• •3. Cohort 2: Have never received any type of pancreatic cancer vaccine/immunotherapy, had the Whipple surgery within 18 months and completed the planned adjuvant chemotherapy and/or chemoradiation.
• •4. Cohorts 1, 3, 4 and 5: Received the last irradiated GM-CSF transfected allogeneic pancreatic cell lines Panc 10.05 and Panc 6.03 at least 6-12 months prior.
• •5. Has received the last anti-cancer therapy at least 28 days ago.
• •6. Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
• •7. Has provided informed consent.
• •8. Has adequate hematologic function.(Hemoglobin ≥ 9 g/dL ANC ≥ 1500/mm3 Platelets ≥ 100,000 K/ mm3).
• •9. Has adequate renal function (Serum creatinine ≤ 2 mg/dL).
• •10. Has adequate hepatic function. (Bilirubin ≤ 2.0 mg/dl, unless known Gilbert's Syndrome; AST, ALT and amylase ≤ 2x upper limit of normal, Alk Phos ≤ 5x upper limit of normal).
• •11. Agree to use adequate birth control, if of childbearing potential.